I am a C-Suite Business Leader and Board Director with extensive experience building global multinational pharmaceutical, mid-size, and small biotech companies. I have proven success in developing global programs, leading all phases of drug development through commercialization, and successfully negotiating with the FDA and global health authorities.Additionally, I have significant board experience advising both publicly traded and private companies in healthcare.Executive Highlights Include:► Global development head, leading the successful build-out, growth, and management of global drug development organizations and portfolios as COO and CDO across several therapeutic areas and companies including Endocrine Disorders, Cardiovascular, Anti-infectives, Antivirals, Central Nervous System Disorders, Women’s Health, as well as a number of orphan indications.► Commercial success leading global development for approved and registered products – Orbactiv, Natpara, Clozaril, Fanapt, and Valdoxan – and late-stage products including biologics, small molecules, and devices. Additionally, co-led building, staffing, and operationalizing NPS Pharma International commercial organization in US, EU, Japan, and Latin America to support the approval and launch of Revestive and Natpara/Natpar.► Deep regulatory expertise working with regulatory bodies worldwide, including FDA, EMA (European Union), C-FDA (China), PMDA (Japan), and health authorities in India and Australia. Led NPS through a successful Advisory Committee Meeting with the FDA which was pivotal to the $5.2B acquisition of NPS by Shire.► Selected member of the inaugural class of Women in Bio/GW University Boardroom Ready Program.► Serve as the face of companies with investors/potential investors, Board of Directors, regulatory authorities, analysts, potential partners, and clinicians, translating/communicating value story, corporate strategy, and clinical data.